002332 仙琚制药
已收盘 11-22 15:00:00
资讯
新帖
简况
【机构调研记录】长盛基金调研博腾股份、仙琚制药等13只个股(附名单)
证券之星 · 10-29
【机构调研记录】长盛基金调研博腾股份、仙琚制药等13只个股(附名单)
【机构调研记录】长安基金调研大华股份、仙琚制药等5只个股(附名单)
证券之星 · 10-29
【机构调研记录】长安基金调研大华股份、仙琚制药等5只个股(附名单)
10月28日仙琚制药涨6.38%,兴业兴睿两年持有混合A基金重仓该股
证券之星 · 10-28
10月28日仙琚制药涨6.38%,兴业兴睿两年持有混合A基金重仓该股
仙琚制药(002332.SZ)发布前三季度业绩,净利润5.3亿元,同比增长12.42%
智通财经网 · 10-25
仙琚制药(002332.SZ)发布前三季度业绩,净利润5.3亿元,同比增长12.42%
仙琚制药(002332)10月10日股东户数2.5万户,较上期增加4.17%
证券之星 · 10-18
仙琚制药(002332)10月10日股东户数2.5万户,较上期增加4.17%
仙琚制药最新公告:甲磺酸倍他司汀片药品注册申请获受理
证券之星 · 10-16
仙琚制药最新公告:甲磺酸倍他司汀片药品注册申请获受理
仙琚制药(002332.SZ):甲磺酸倍他司汀片药品注册申请获得受理
智通财经 · 10-16
仙琚制药(002332.SZ):甲磺酸倍他司汀片药品注册申请获得受理
仙琚制药最新公告:甲硫酸新斯的明注射液通过一致性评价
证券之星 · 10-14
仙琚制药最新公告:甲硫酸新斯的明注射液通过一致性评价
仙琚制药(002332.SZ):甲硫酸新斯的明注射液通过仿制药一致性评价
智通财经 · 10-14
仙琚制药(002332.SZ):甲硫酸新斯的明注射液通过仿制药一致性评价
天风证券:给予仙琚制药买入评级,目标价位17.37元
证券之星 · 10-11
天风证券:给予仙琚制药买入评级,目标价位17.37元
仙琚制药(002332)10月8日主力资金净买入1914.81万元
证券之星 · 10-09
仙琚制药(002332)10月8日主力资金净买入1914.81万元
仙琚制药:截止近期,公司股东人数为2万4千余人
证券之星 · 09-24
仙琚制药:截止近期,公司股东人数为2万4千余人
仙琚制药新提交1件商标注册申请
证券之星 · 09-07
仙琚制药新提交1件商标注册申请
【机构调研记录】永赢基金调研仙琚制药、阿特斯等7只个股(附名单)
证券之星 · 09-05
【机构调研记录】永赢基金调研仙琚制药、阿特斯等7只个股(附名单)
【机构调研记录】天治基金调研金牌家居、仙琚制药等4只个股(附名单)
证券之星 · 09-05
【机构调研记录】天治基金调研金牌家居、仙琚制药等4只个股(附名单)
【机构调研记录】大成基金调研仙琚制药、阿特斯等3只个股(附名单)
证券之星 · 09-05
【机构调研记录】大成基金调研仙琚制药、阿特斯等3只个股(附名单)
【机构调研记录】南方基金调研仙琚制药、阿特斯等12只个股(附名单)
证券之星 · 09-05
【机构调研记录】南方基金调研仙琚制药、阿特斯等12只个股(附名单)
德邦证券给予仙琚制药买入评级,制剂集采影响逐步出清 多重催化有望带来新一轮增长
每日经济新闻 · 09-01
德邦证券给予仙琚制药买入评级,制剂集采影响逐步出清 多重催化有望带来新一轮增长
德邦证券:给予仙琚制药买入评级
证券之星 · 09-01
德邦证券:给予仙琚制药买入评级
【机构调研记录】鹏华基金调研光威复材、仙琚制药等19只个股(附名单)
证券之星 · 08-29
【机构调研记录】鹏华基金调研光威复材、仙琚制药等19只个股(附名单)
加载更多
公司概况
公司名称:
浙江仙琚制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-01-12
主营业务:
浙江仙琚制药股份有限公司主营业务为甾体原料药和制剂的研制、生产与销售。公司主要产品分为皮质激素类药物、性激素类药物(妇科及计生用药)、麻醉肌松类药物和呼吸科类药物四大类。2023年,在中国医药工业信息中心主办的2023年(第40届)全国医药工业信息年会发布的“2022年度中国医药工业百强榜”中公司位列第70位,同时公司还首次获得“中国医药研发产品线最佳工业企业”“国家企业技术中心”“国家知识产权优势企业”“浙江知识产权示范企业”等诸多荣誉,顺利通过EcoVadis评级荣获银牌勋章。
发行价格:
8.20
{"stockData":{"symbol":"002332","market":"SZ","secType":"STK","nameCN":"仙琚制药","latestPrice":12.01,"timestamp":1732259028000,"preClose":12.75,"halted":0,"volume":23296958,"delay":0,"floatShares":985000000,"shares":989000000,"eps":0.6285,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.74,"latestTime":"11-22 15:00:00","open":12.75,"high":12.77,"low":12.01,"amount":287000000,"amplitude":0.0596,"askPrice":12.03,"askSize":136,"bidPrice":12.01,"bidSize":97,"shortable":0,"etf":0,"ttmEps":0.6285,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1732498200000},"adr":0,"adjPreClose":12.75,"symbolType":"stock","openAndCloseTimeList":[[1732239000000,1732246200000],[1732251600000,1732258800000]],"highLimit":14.03,"lowLimit":11.48,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":989204866,"pbRate":2.1,"roa":"--","roe":"8.96%","epsLYR":0.57,"committee":0.05226,"marketValue":11880000000,"floatMarketCap":11825000000,"peRate":19.10899,"changeRate":-0.058,"turnoverRate":0.0237,"status":1},"requestUrl":"/m/hq/s/002332","defaultTab":"news","newsList":[{"id":"2479749823","title":"【机构调研记录】长盛基金调研博腾股份、仙琚制药等13只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479749823","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479749823?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:05","pubTimestamp":1730160347,"startTime":"0","endTime":"0","summary":"长盛基金成立于1999年,截至目前,资产管理规模961.2亿元,排名63/207;资产管理规模622.02亿元,排名62/207;管理公募基金数135只,排名50/207;旗下公募基金经理22人,排名62/207。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008138.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","300363","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2479287498","title":"【机构调研记录】长安基金调研大华股份、仙琚制药等5只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2479287498","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479287498?lang=zh_cn&edition=full","pubTime":"2024-10-29 08:05","pubTimestamp":1730160343,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及10月28日披露的机构调研信息,长安基金近期对5家上市公司进行了调研,相关名单如下:1)大华股份 个股亮点:公司提供安防系统集成服务。旗下最近一年表现最佳的公募基金产品为长安鑫兴混合A,最新单位净值为1.9,近一年增长24.09%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102900008133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0070","IE0032431581.USD","002332","BK0239","SG9999014674.SGD","BK0041","BK0183","BK0061","BK0214","BK0187","BK0188","BK0028","BK0197","BK0077","BK0175","BK0100","002236"],"gpt_icon":0},{"id":"2478178031","title":"10月28日仙琚制药涨6.38%,兴业兴睿两年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2478178031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478178031?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:22","pubTimestamp":1730103765,"startTime":"0","endTime":"0","summary":"证券之星消息,10月28日仙琚制药涨6.38%,收盘报13.51元,换手率3.0%,成交量29.52万手,成交额3.92亿元。根据2024基金Q3季报公募基金重仓股数据,重仓该股的公募基金共52家,其中持有数量最多的公募基金为兴业兴睿两年持有混合A。兴业兴睿两年持有混合A目前规模为29.04亿元,最新净值0.7995,较上一交易日上涨0.99%,近一年上涨5.49%。兴业兴睿两年持有混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800020083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SG9999014674.SGD","BK0028","002332"],"gpt_icon":0},{"id":"2478604501","title":"仙琚制药(002332.SZ)发布前三季度业绩,净利润5.3亿元,同比增长12.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478604501","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478604501?lang=zh_cn&edition=full","pubTime":"2024-10-25 18:03","pubTimestamp":1729850580,"startTime":"0","endTime":"0","summary":"仙琚制药(002332.SZ)发布2024年三季度报告,前三季度,公司实现营业收入32.37亿元,同比下降0.01%。归属于上市公司股东的净利润5.3亿元,同比增长12.42%。归属于上市公司股东的扣除非经常性损益的净利润5.21亿元,同比增长12.82%。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-25/doc-inctuivx1593227.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-10-25/doc-inctuivx1593227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002332"],"gpt_icon":0},{"id":"2476406884","title":"仙琚制药(002332)10月10日股东户数2.5万户,较上期增加4.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476406884","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476406884?lang=zh_cn&edition=full","pubTime":"2024-10-18 17:07","pubTimestamp":1729242479,"startTime":"0","endTime":"0","summary":"证券之星消息,近日仙琚制药披露,截至2024年10月10日公司股东户数为2.5万户,较9月20日增加1000.0户,增幅为4.17%。在化学制药行业个股中,仙琚制药股东户数低于行业平均水平,截至10月10日,化学制药行业平均股东户数为3.18万户。从股价来看,2024年9月20日至2024年10月10日,仙琚制药区间涨幅为14.07%,在此期间股东户数增加1000.0户,增幅为4.17%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101800027745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","002332","BK0028","BK0239"],"gpt_icon":0},{"id":"2475955667","title":"仙琚制药最新公告:甲磺酸倍他司汀片药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2475955667","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475955667?lang=zh_cn&edition=full","pubTime":"2024-10-16 17:21","pubTimestamp":1729070468,"startTime":"0","endTime":"0","summary":"仙琚制药公告,公司近日收到国家药监局下发的甲磺酸倍他司汀片境内生产药品注册受理通知书。该药品用于下列疾病伴发的眩晕、头晕感:梅尼埃病、梅尼埃综合征、眩晕症。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101600028520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2475937738","title":"仙琚制药(002332.SZ):甲磺酸倍他司汀片药品注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2475937738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475937738?lang=zh_cn&edition=full","pubTime":"2024-10-16 16:51","pubTimestamp":1729068682,"startTime":"0","endTime":"0","summary":"智通财经APP讯,仙琚制药(002332.SZ)发布公告,公司于近日收到国家药品监督管理局下发的甲磺酸倍他司汀片境内生产药品注册受理通知书。据悉,甲磺酸倍他司汀片,规格为6mg,参比制剂为原研的上市药品,其持证商为卫材(中国)药业有限公司,其英文名/商品名为Betahistine Mesilate Tablets/敏使朗。甲磺酸倍他司汀片最早由日本Eisai Co.,Ltd.研发,商品名为Merislon®。适应症为用于下列疾病伴发的眩晕、头晕感:梅尼埃病、梅尼埃综合征、眩晕症。本次公司申报的甲磺酸倍他司汀片规格与参比制剂上市的规格一致,按化学药品4类进行申报。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1194771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","002332","BK0028","BK0239"],"gpt_icon":0},{"id":"2475330546","title":"仙琚制药最新公告:甲硫酸新斯的明注射液通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2475330546","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475330546?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:51","pubTimestamp":1728895899,"startTime":"0","endTime":"0","summary":"仙琚制药公告,公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》,公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101400020559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SG9999014674.SGD","BK0028","002332"],"gpt_icon":0},{"id":"2475334729","title":"仙琚制药(002332.SZ):甲硫酸新斯的明注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2475334729","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475334729?lang=zh_cn&edition=full","pubTime":"2024-10-14 16:22","pubTimestamp":1728894167,"startTime":"0","endTime":"0","summary":"智通财经APP讯,仙琚制药(002332.SZ)发布公告,公司于近日收到国家药品监督管理局核准签发的关于甲硫酸新斯的明注射液的《药品补充申请批准通知书》(通知书编号:2024B047132024B04714),公司甲硫酸新斯的明注射液通过仿制药质量和疗效一致性评价。据悉,甲硫酸新斯的明注射液是抗胆碱酯酶药。用于手术结束时拮抗非去极化肌肉松弛药的残留肌松作用,用于重症肌无力,手术后功能性肠胀气及尿潴留等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1193358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SG9999014674.SGD","002332","BK0028","BK0239"],"gpt_icon":0},{"id":"2474037235","title":"天风证券:给予仙琚制药买入评级,目标价位17.37元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474037235","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474037235?lang=zh_cn&edition=full","pubTime":"2024-10-11 14:15","pubTimestamp":1728627319,"startTime":"0","endTime":"0","summary":"天风证券股份有限公司杨松近期对仙琚制药进行研究并发布了研究报告《甾体类全链条龙头,制剂新品种商业化潜力可观》,本报告对仙琚制药给出买入评级,认为其目标价位为17.37元,当前股价为12.45元,预期上涨幅度为39.52%。给予2025年20倍PE,目标价17.37元/股。首次覆盖,给予“买入”评级。最新盈利预测明细如下:该股最近90天内共有13家机构给出评级,买入评级12家,增持评级1家;过去90天内机构目标均价为14.83。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024101100015775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","601162"],"gpt_icon":0},{"id":"2474977230","title":"仙琚制药(002332)10月8日主力资金净买入1914.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2474977230","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474977230?lang=zh_cn&edition=full","pubTime":"2024-10-09 09:27","pubTimestamp":1728437221,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年10月8日收盘,仙琚制药报收于13.78元,上涨2.07%,换手率3.22%,成交量31.64万手,成交额4.36亿元。近5日资金流向一览见下表:仙琚制药融资融券信息显示,融资方面,当日融资买入4153.6万元,融资偿还2126.89万元,融资净买入2026.71万元。仙琚制药主营业务:甾体原料药和制剂的研制、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024100900005877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2469463975","title":"仙琚制药:截止近期,公司股东人数为2万4千余人","url":"https://stock-news.laohu8.com/highlight/detail?id=2469463975","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469463975?lang=zh_cn&edition=full","pubTime":"2024-09-24 18:01","pubTimestamp":1727172079,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)09月24日在投资者关系平台上答复投资者关心的问题。投资者:请问截止2024年9月20日公司股东人数是多少?谢谢仙琚制药董秘:您好!截止近期,公司股东人数为2万4千余人。感谢您的关注。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024092400029588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2465604528","title":"仙琚制药新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2465604528","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465604528?lang=zh_cn&edition=full","pubTime":"2024-09-07 13:30","pubTimestamp":1725687042,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示,近日浙江仙琚制药股份有限公司新提交1件商标注册申请。商标申请详情如下:今年以来浙江仙琚制药股份有限公司新申请注册商标2件,截止目前公司共持有注册商标356件,另有16件商标尚在注册申请中。数据来源:企查查以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090700006993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2465354554","title":"【机构调研记录】永赢基金调研仙琚制药、阿特斯等7只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2465354554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465354554?lang=zh_cn&edition=full","pubTime":"2024-09-05 08:02","pubTimestamp":1725494545,"startTime":"0","endTime":"0","summary":";公司研发项目有:面向半导体玻璃基板激光打孔高精度气浮定位平台开发永赢基金成立于2013年,截至目前,资产管理规模4937.98亿元,排名23/207;资产管理规模3219.44亿元,排名16/207;管理公募基金数244只,排名24/207;旗下公募基金经理43人,排名24/207。旗下最近一年表现最佳的公募基金产品为永赢股息优选A,最新单位净值为1.34,近一年增长24.68%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090500006283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0224","SG9999014674.SGD","BK0028","002332","688472","BK0239"],"gpt_icon":0},{"id":"2465554805","title":"【机构调研记录】天治基金调研金牌家居、仙琚制药等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2465554805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465554805?lang=zh_cn&edition=full","pubTime":"2024-09-05 08:02","pubTimestamp":1725494521,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及9月4日披露的机构调研信息,天治基金近期对4家上市公司进行了调研,相关名单如下:1)金牌家居 个股亮点:金23转债于2023-05-16上市;子公司智小金在成立之初就在人工智能方向进行布局和深耕,并在多款产品上有所应用。旗下最近一年表现最佳的公募基金产品为天治鑫利纯债债券A,最新单位净值为1.12,近一年增长6.68%。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090500006253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","603180","SG9999014674.SGD","BK0260","BK0186","002332","BK0239"],"gpt_icon":0},{"id":"2465804554","title":"【机构调研记录】大成基金调研仙琚制药、阿特斯等3只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2465804554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465804554?lang=zh_cn&edition=full","pubTime":"2024-09-05 08:02","pubTimestamp":1725494520,"startTime":"0","endTime":"0","summary":"大成基金成立于1999年,截至目前,资产管理规模3013.4亿元,排名31/207;资产管理规模2022.59亿元,排名25/207;管理公募基金数367只,排名17/207;旗下公募基金经理46人,排名21/207。旗下最新募集公募基金产品为大成稳康6个月持有期债券A,类型为债券型-长债,集中认购期2024年9月2日至2024年9月13日。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090500006252.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","688472","BK0028","002332","BK0239","BK0224"],"gpt_icon":0},{"id":"2465554318","title":"【机构调研记录】南方基金调研仙琚制药、阿特斯等12只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2465554318","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2465554318?lang=zh_cn&edition=full","pubTime":"2024-09-05 08:01","pubTimestamp":1725494511,"startTime":"0","endTime":"0","summary":";公司产品在汽车领域的应用:发动机控制系统、视频识别系统、智能驾驶辅助系统等南方基金成立于1998年,截至目前,资产管理规模12130.21亿元,排名4/207;资产管理规模5776.59亿元,排名6/207;管理公募基金数694只,排名4/207;旗下公募基金经理89人,排名6/207。旗下最近一年表现最佳的公募基金产品为南方融尚再融资混合,最新单位净值为1.84,近一年增长37.41%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090500006244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0224","002332","SG9999014674.SGD","688472","BK0028","BK0239"],"gpt_icon":0},{"id":"2464886480","title":"德邦证券给予仙琚制药买入评级,制剂集采影响逐步出清 多重催化有望带来新一轮增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2464886480","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464886480?lang=zh_cn&edition=full","pubTime":"2024-09-01 20:08","pubTimestamp":1725192516,"startTime":"0","endTime":"0","summary":"德邦证券09月01日发布研报称,给予仙琚制药(002332.SZ,最新价:11.5元)买入评级。评级理由主要包括:1)制剂:集采影响逐步出清,新品陆续放量增长;2)原料药:发挥法规市场注册优势,积极拓展新客户。风险提示:行业政策变动风险、产品销售不及预期风险、研发风险等。AI点评:仙琚制药近一个月获得2份券商研报关注,买入1家。文章来源:每日经济新闻原标题:德邦证券给予仙琚制药买入评级,制剂集采影响逐步出清,多重催化有望带来新一轮增长","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090120475695d91165&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024090120475695d91165&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["161027","002332","603056"],"gpt_icon":0},{"id":"2464923100","title":"德邦证券:给予仙琚制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2464923100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2464923100?lang=zh_cn&edition=full","pubTime":"2024-09-01 20:06","pubTimestamp":1725192384,"startTime":"0","endTime":"0","summary":"德邦证券股份有限公司周新明,吴明华近期对仙琚制药进行研究并发布了研究报告《制剂集采影响逐步出清,多重催化有望带来新一轮增长》,本报告对仙琚制药给出买入评级,当前股价为11.5元。2024H1原料药及中间体销售收入9.1亿元,同比下降9%。维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有8家机构给出评级,买入评级7家,增持评级1家;过去90天内机构目标均价为15.37。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024090100003430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","161027"],"gpt_icon":0},{"id":"2463442363","title":"【机构调研记录】鹏华基金调研光威复材、仙琚制药等19只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2463442363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2463442363?lang=zh_cn&edition=full","pubTime":"2024-08-29 08:03","pubTimestamp":1724889826,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及8月28日披露的机构调研信息,鹏华基金近期对19家上市公司进行了调研,相关名单如下:1)光威复材 个股亮点:公司主营产品为碳纤维及织物、碳梁、预浸料、制品;公司是国产碳纤维航空航天应用领域的核心供应商。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082900009045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0239","BK0028","SG9999014674.SGD","300699"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-01-12","address":"浙江省台州市仙居县仙药路1号","stockEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0087},{"period":"3month","weight":0.0759},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.0861},{"period":"ytd","weight":0.0232}],"companyName":"浙江仙琚制药股份有限公司","boardCode":"AI0027","perCapita":"39382股","boardName":"医药制造业","registeredCapital":"98920万元","compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.1808},{"period":"6month","weight":0.0911},{"period":"1year","weight":0.1074},{"period":"ytd","weight":0.1329}],"survey":" 浙江仙琚制药股份有限公司主营业务为甾体原料药和制剂的研制、生产与销售。公司主要产品分为皮质激素类药物、性激素类药物(妇科及计生用药)、麻醉肌松类药物和呼吸科类药物四大类。2023年,在中国医药工业信息中心主办的2023年(第40届)全国医药工业信息年会发布的“2022年度中国医药工业百强榜”中公司位列第70位,同时公司还首次获得“中国医药研发产品线最佳工业企业”“国家企业技术中心”“国家知识产权优势企业”“浙江知识产权示范企业”等诸多荣誉,顺利通过EcoVadis评级荣获银牌勋章。","serverTime":1732284091372,"listedPrice":8.2,"stockholders":"25000人(较上一季度增加4.41%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仙琚制药,002332,仙琚制药股票,仙琚制药股票老虎,仙琚制药股票老虎国际,仙琚制药行情,仙琚制药股票行情,仙琚制药股价,仙琚制药股市,仙琚制药股票价格,仙琚制药股票交易,仙琚制药股票购买,仙琚制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}